FONDAPARINUX

FONDAPARINUX: Fondaparinux is a medication primarily used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism. It belongs to the class of drugs known as anticoagulants or blood thinners.

The mechanism of action of fondaparinux involves its ability to selectively inhibit a specific clotting factor in the blood called Factor Xa. By inhibiting Factor Xa, fondaparinux prevents the formation of blood clots. It does not directly affect the activity of another clotting factor called thrombin.

The recommended dose of fondaparinux for the prevention of DVT after surgery is typically 2.5 mg once daily, administered as a subcutaneous injection. The duration of treatment varies depending on the specific medical condition and individual patient factors. For treatment of acute DVT or pulmonary embolism, the dose is usually increased to 7.5 mg once daily.

Some common side effects of fondaparinux include bruising at the injection site, bleeding, anemia, and nausea. Severe bleeding, including internal bleeding, can occasionally occur and requires immediate medical attention. Other rare but serious side effects may include allergic reactions, thrombocytopenia (low platelet count), or elevation of liver enzymes.

It is important to note that fondaparinux should be used with caution in patients with a history of bleeding disorders, severe renal impairment, or low body weight. It may also interact with other medications, so it is essential to inform your healthcare provider about any other drugs you are taking.

As with any medication, it is always recommended to consult with a healthcare professional for personalized advice and guidance.